Windtree Therapeutics (WINT) Stock Price, News & Analysis

Company Overview

Windtree Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative therapies for acute cardiovascular and pulmonary conditions. The company leverages its proprietary KL4 surfactant technology to address diseases marked by surfactant deficiency or dysfunction, with a primary focus on acute respiratory distress syndrome (ARDS) in adults and respiratory distress syndrome (RDS) in premature infants.

The company’s lead platform comprises synthetic peptide‐based surfactants designed to restore lung function by reducing surface tension in the alveoli. Windtree’s pipeline includes aerosolized and intratracheal formulations intended for rapid distribution in the lung, including programs that have advanced through preclinical studies and early-stage clinical trials. These programs aim to offer an alternative to animal-derived surfactants and to target patient populations with significant unmet medical needs.

Headquartered in Warrington, Pennsylvania, Windtree collaborates with academic research centers and clinical investigators across the United States and Europe to conduct its development programs. The company’s activities encompass formulation optimization, toxicology testing, and multi-site clinical evaluations, supported by partnerships that extend its reach into critical care and neonatal intensive care settings.

Under the leadership of President and CEO Michael Ott, Windtree maintains a management team with extensive experience in drug development, regulatory affairs and commercial strategy. The organization is committed to advancing its pipeline through regulatory interactions and clinical milestones in pursuit of therapies that can improve outcomes for patients with serious cardiopulmonary disorders.

Key Stats

• Today's Range: $0.0126 to $0.0185
• 50-Day Range: $0.01 to $0.03
• 52-Week Range: $0.01 to $1.86
• Volume: 64,397 shs
• Average Volume: 375,435 shs
• Market Capitalization: $634.33 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/19/2025
• Today: 5/25/2026
• Next Earnings (Estimated): 5/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:WINT
• CIK: 946486
• Web: www.windtreetx.com
• Phone: (215) 488-9300
• Fax: 215-488-9301
• Employees: 30
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($8.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -207.34%
• Return on Assets: -50.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.43
• Quick Ratio: 0.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.98 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 44,988,000
• Free Float: 3,656,000
• Market Cap: $634.33 thousand
• Optionable: Not Optionable
• Beta: 1.75